Form 4: Terns Pharmaceuticals Director Granted 45,000 Stock Options

Jeffrey B Kindler, a Director at Terns Pharmaceuticals, Inc., was granted 45,000 stock options with an exercise price of $4.10, aligning his interests with long-term shareholder value.

Summary

• Jeffrey B Kindler, a Director of Terns Pharmaceuticals, Inc. (TERN), was granted 45,000 stock options.
• The stock options have an exercise price of $4.10 per share.
• The transaction date for this grant was June 11, 2025.
• The options will vest in full on the earlier of (i) the first anniversary of the grant date (June 11, 2026) or (ii) immediately prior to the Annual Meeting following the date of grant.
• The expiration date for these options is June 10, 2035.
• Following this transaction, Mr. Kindler beneficially owns 45,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive for corporate governance as it aligns the director's interests with shareholders. It does not contain any negative news or significant unexpected events.

Positives

• The grant of stock options to a director aligns management's long-term interests with those of shareholders, as the options gain value only if the company's stock price increases.
• The exercise price of $4.10 provides a clear benchmark for future stock performance relative to the grant.

Future Outlook

The grant of stock options with a future vesting schedule indicates an expectation of continued service from the director and a long-term incentive for value creation, aligning with the company's future performance.

Industry Context

The granting of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of equity compensation to attract, retain, and incentivize board members by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• Granting stock options to directors is a widely accepted compensation practice across the biotechnology and pharmaceutical sectors, similar to structures seen at comparable development-stage biopharmaceutical companies.
• This method of compensation is designed to align the interests of the board with those of shareholders, a common governance principle in the industry.

Corporate Governance

Related Party Transactions

• The grant of stock options to Jeffrey B Kindler, a Director, constitutes a related party transaction as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can influence overall company culture and talent retention.

Next Steps

• The stock options will vest on the earlier of June 11, 2026, or immediately prior to the Annual Meeting following the grant date.
• The director may exercise the vested options at any time before the expiration date of June 10, 2035.

Key Dates

Recommendation

Keywords

Terns Pharmaceuticals, TERN, Stock Option, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership